Fingerstick blood test cartridge may improve childhood TB diagnosis
A three-gene Mycobacterium tuberculosis host response cartridge using a fingerstick blood sample has shown promising diagnostic accuracy for childhood tuberculosis, researchers report in The Lancet Infectious Diseases.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Diffusing capacity of lung for carbon monoxide predicts SLE disease severity
The diffusing capacity of the lungs for carbon monoxide could be a surrogate marker for overall disease severity in patients with systemic lupus erythematosus, suggest researchers in Rheumatology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Rationale for antiviral therapy in new-onset type 1 diabetes
Antiviral therapy may preserve residual insulin production in children and adolescents newly diagnosed with type 1 diabetes, suggest findings from the DiViD intervention study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
DOPA decarboxylase: a ‘highly promising’ biomarker for Parkinsonian disorders
DOPA decarboxylase could be an effective biomarker for dopaminergic dysfunction, detecting early and preclinical Lewy body disease and atypical Parkinsonian disorders, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Complete remission best for tapering SLE treatment
To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Mezigdomide plus dexamethasone show ‘preliminary efficacy’ for refractory multiple myeloma
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Four distinct Kawasaki disease subgroups identified
Distinct subgroups exist among children with Kawasaki disease, say researchers in findings that provide some clues to the clinical variability of the disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cushing’s syndrome comorbidities require surveillance beyond remission
Experts emphasize the need for long-term surveillance for all patients with Cushing’s syndrome, after their systematic literature review showed associated comorbidities often continue well beyond remission.
Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
